MedTrace Logo

Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects

NCT00729508 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2009-07-08

No results posted yet for this study

Summary

Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma. Cat-PAD is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of cat allergy. This study will investigate the efficacy of 4 treatment regimens of Cat-PAD in cat allergic subjects following challenge to cat allergen in an environmental exposure chamber (EEC).

Conditions

  • Cat Allergy

Interventions

BIOLOGICAL

Cat-PAD

Cat-PAD dose 2X 4 administrations 2 weeks apart

BIOLOGICAL

Cat-PAD

Cat-PAD dose 1X 4 administrations 2 weeks apart

BIOLOGICAL

Cat-PAD

Cat-PAD dose 1X 4 administrations 4 weeks apart

BIOLOGICAL

Cat-PAD

Cat-PAD dose 1X 8 administrations 2 weeks apart

BIOLOGICAL

Cat-PAD

Placebo

Sponsors & Collaborators

  • Circassia Limited

    lead INDUSTRY

Principal Investigators

  • Deepen Patel, MD · Allied Research International Inc-Cetero Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-04-30
Completion
2009-05-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00729508 on ClinicalTrials.gov